首页> 美国卫生研究院文献>Iranian Journal of Public Health >Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings

【2h】

Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings

机译：在哈萨克斯坦医疗机构中口服蛋白酶抑制剂与聚乙二醇化干扰素-A2b和利巴韦林共同给药的成本效益仅适用于丙型肝炎患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:The triple therapy including peginterferon, ribavirin and protease inhibitors was more effective compared to the combination of only peginterferon and ribavirin. This study aimed to assess the cost-effectiveness of triple treatment in either treatment-naïve and treatment-experienced patients in Kazakhstan.

机译：背景：与仅使用聚乙二醇干扰素和利巴韦林的组合相比，包括聚乙二醇干扰素，利巴韦林和蛋白酶抑制剂的三联疗法更有效。这项研究的目的是评估哈萨克斯坦未经治疗和有经验的患者进行三联治疗的成本效益。

著录项

期刊名称 Iranian Journal of Public Health
作者
Alima ALMADIYEVA; Serik IBRAYEV; Assiya TURGAMBAYEVA; Alexandr KOSTYUK; Zayituna KHISMETOVA; Zhanar AKHMETOVA;
展开▼
作者单位

展开▼
年(卷),期 2018(47),12
年度 2018
页码 1845–1853
总页数 9
原文格式 PDF
正文语种
中图分类公共卫生工程;
关键词
Hepatitis C Antiviral treatment Protease inhibitors Cost-effectiveness;

机译：丙型肝炎;抗病毒治疗;蛋白酶抑制剂;成本效益;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings [J] . Iranian journal of public health. . 2018,第12期

机译：哈萨克斯坦医疗机构中口服蛋白酶抑制剂与聚乙二醇干扰素-A2b和利巴韦林共同给药的成本效益
2. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-alpha 2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore [J] . Dan Yock Young, Ferrante Shannon A., Elbasha Elamin H., Antiviral therapy . 2015,第2期

机译：Boceprevir与聚乙二醇干扰素-α2b和利巴韦林联用的成本效益仅在新加坡具有丙型肝炎基因型1的患者中
3. Cost-Effectiveness of IL28B Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection [J] . Bock Jonathan A., Fairley Kimberly J., Smith Robert E., Public health genomics . 2014,第5a6期

机译：IL28B基因型蛋白酶抑制剂三联疗法与标准治疗在丙型肝炎基因型2或3感染患者中的成本效益比较
4. Cost-Effectiveness of IL28B Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection [O] . Jonathan A. Bock, Kimberly J. Fairley, Robert E. Smith, -1

机译：IL28B基因型蛋白酶抑制剂三联疗法与丙型肝炎基因型2或3感染患者的标准治疗相比的成本效益
5. PIN50 The Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination with Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis from the Perspective of the Scottish National Health Service (NHS) [O] . Nikoglou E., Humphreys S., El khoury A., 2011

机译：PIN50 Boceprevir与聚乙二醇干扰素-Alfa和Ribavirin联合治疗基因型1型慢性丙型肝炎患者的临床疗效和成本效益：从苏格兰国家卫生服务局（NHS）的角度进行试验分析

Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅